专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

131. 发明申请

US20090175893A1 Albumin-Fused Anti-Angiogenesis Peptides 审中-公开
标题翻译：白蛋白融合抗血管生成肽
公开(公告)号：US20090175893A1
公开(公告)日：2009-07-09
申请号：US12358815
申请日：2009-01-23
申请人： Peter Mertins , Ilhan Celik , Oliver Kisker , Darrell Sleep , Joanna Hay , Hans-Peter Hauser
发明人： Peter Mertins , Ilhan Celik , Oliver Kisker , Darrell Sleep , Joanna Hay , Hans-Peter Hauser
IPC分类号： A61K39/00 , A61K38/16
CPC分类号： A61K38/39 , A01K2217/05 , A61K9/0019 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0005 , A61K47/643 , A61K48/00 , A61K2039/53 , C07K14/005 , C07K14/47 , C07K14/765 , C07K14/78 , C07K14/8114 , C07K2319/00 , C07K2319/31 , C12N15/62 , C12N2740/16122 , C12Y301/26003
摘要： The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinopathy, progressive macular degeneration or rheumatoid arthritis.
摘要翻译：本发明涉及包含血管生成抑制肽（例如内皮抑素肽（包括但不限于其片段和变体））的蛋白质，其表现出与白蛋白融合或缀合的抗逆转录病毒活性（包括但不限于片段或变体的白蛋白）。这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法，载体和/或宿主细胞。本发明还涉及抑制血管内皮细胞增殖和肿瘤血管生成诱导的细胞融合的组合物和方法。本发明还涉及预防原发性肿瘤和转移瘤的生长或促进消退的组合物和方法; 并用于治疗癌症，糖尿病性视网膜病变，进行性黄斑变性或类风湿性关节炎。

132. 发明授权

US07556813B2 Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides 失效
标题翻译：包含共价连接到两个或更多个合成的HIV gp41 HR1和/或HR2肽的聚合物的抗病毒肽 - 聚合物缀合物
公开(公告)号：US07556813B2
公开(公告)日：2009-07-07
申请号：US10671282
申请日：2003-09-24
申请人： Brian Bray , Myung-Chol Kang , Nicolai Tvermoes , Daniel Kinder , John William Lackey , Huyi Zhang
发明人： Brian Bray , Myung-Chol Kang , Nicolai Tvermoes , Daniel Kinder , John William Lackey , Huyi Zhang
IPC分类号： A61K39/3085 , A61K39/21
CPC分类号： C07K14/005 , A61K38/00 , A61K47/60 , C12N2740/16122
摘要： Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
摘要翻译：提供了包含具有可操作地结合有不少于两个来自HIV gp41的合成肽的两分子的聚合物的缀合物; 使用这些缀合物通过添加有效抑制病毒感染的量来抑制HIV向目标细胞传播的方法; 以及通过将每个分子的合成肽通过反应性官能团可操作地结合到聚合物来生产缀合物的方法。

133. 发明授权

US07544665B2 Synthesis using peptide intermediate fragments 失效
标题翻译：使用肽中间体片段进行合成
公开(公告)号：US07544665B2
公开(公告)日：2009-06-09
申请号：US11322394
申请日：2005-12-30
申请人： Hiralal N. Khatri , Yeun-Kwei Han , David A. Johnston , L. Mark Hodges
发明人： Hiralal N. Khatri , Yeun-Kwei Han , David A. Johnston , L. Mark Hodges
IPC分类号： A61K38/00 , C07K1/02
CPC分类号： C07K14/005 , A61K38/00 , C12N2740/16122
摘要： Methods for the solid phase synthesis of T-1249 peptides and peptide intermediates, in particular methods involving synthesizing T-1249 peptide intermediates at low loading factors to produce products having excellent purity and yield.
摘要翻译： T-1249肽和肽中间体的固相合成方法，特别是涉及在低负载因子下合成T-1249肽中间体以产生具有优异纯度和产率的产物的方法。

134. 发明申请

US20090117572A1 Cell-Based Fluorescence Resonance Energy Transfer (FRET) Assays For Clostridial Toxins 有权
标题翻译：用于梭菌毒素的基于细胞的荧光共振能量转移（FRET）测定
公开(公告)号：US20090117572A1
公开(公告)日：2009-05-07
申请号：US12192925
申请日：2008-08-15
申请人： Ester Fernandez-Salas , Lance E. Steward , Kei Roger Aoki
发明人： Ester Fernandez-Salas , Lance E. Steward , Kei Roger Aoki
IPC分类号： C12Q1/68 , G01N33/569
CPC分类号： C07K14/005 , C07K14/33 , C07K14/4702 , C07K14/4725 , C12N2710/16622 , C12N2740/16122 , C12Q1/37
摘要： The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the donor fluorophore and the acceptor, where resonance energy transfer is exhibited between the donor fluorophore and the acceptor under the appropriate conditions; (b) exciting the donor fluorophore; and (c) determining resonance energy transfer of the contacted cell relative to a control cell, where a difference in resonance energy transfer of the contacted cell as compared to the control cell is indicative of clostridial toxin activity.
摘要翻译：本发明提供了一种通过（a）使样品与包含供体荧光团的梭菌毒素底物的细胞接触来测定梭菌毒素活性的方法; 具有与供体荧光团的发射光谱重叠的吸收光谱的受体; 以及包含介入供者荧光团和受体之间的切割位点的梭菌毒素识别序列，其中在适当条件下在供体荧光团和受体之间显示共振能量转移; （b）激发供体荧光团; 和（c）确定接触细胞相对于对照细胞的共振能量转移，其中与对照细胞相比，所接触的细胞的共振能量转移的差异指示梭菌毒素活性。

135. 发明申请

US20090104229A1 NOVEL USE 审中-公开
标题翻译：新用途
公开(公告)号：US20090104229A1
公开(公告)日：2009-04-23
申请号：US12117205
申请日：2008-05-08
申请人： Gerald VOSS
发明人： Gerald VOSS
IPC分类号： A61K39/00
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/53 , A61K2039/55561 , A61K2039/57 , C07K2319/00 , C12N2740/16122 , C12N2740/16322
摘要： The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gp120 protein or polynucleotide in the manufacture of a vaccine for the prophylactic or therapeutic immunisation of humans against HIV.
摘要翻译：本发明提供了a）HIV Tat蛋白或多核苷酸的用途; 或b）HIV Nef蛋白或多核苷酸; 或c）与HIV Nef蛋白或多核苷酸（Nef-Tat）连接的HIV Tat蛋白或多核苷酸; 和HIV gp120蛋白或多核苷酸在制备用于预防或治疗免疫HIV的疫苗中。

136. 发明申请

US20090099073A1 Albumin Fusion Proteins 审中-公开
公开(公告)号：US20090099073A1
公开(公告)日：2009-04-16
申请号：US11929946
申请日：2007-10-30
申请人： Craig A. Rosen , William A. Haseltine , David J. Ballance , Andrew J. Turner , Steven M. Ruben
发明人： Craig A. Rosen , William A. Haseltine , David J. Ballance , Andrew J. Turner , Steven M. Ruben
IPC分类号： A61K38/38 , C07K14/76 , C07H21/04 , C12N15/00 , C12N5/00 , C12N1/00 , C12P21/06
CPC分类号： C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

137. 发明申请

US20090098161A1 Method of making an immunogenic composition using psoralen inactivated HIV 失效
标题翻译：使用补骨脂素灭活的HIV制备免疫原性组合物的方法
公开(公告)号：US20090098161A1
公开(公告)日：2009-04-16
申请号：US12315777
申请日：2008-12-05
申请人： Nelson M. Karp
发明人： Nelson M. Karp
IPC分类号： A61K39/21 , C12N7/06 , A61P31/18 , A61P37/04
CPC分类号： C12N7/00 , A61K9/0014 , A61K9/0019 , A61K39/00 , A61K39/12 , A61K39/21 , A61K47/12 , A61K2039/523 , A61K2039/5252 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , A61K2039/55511 , A61K2039/55583 , A61K2039/55594 , A61K2039/6018 , C07K14/005 , C12N2710/16243 , C12N2740/16034 , C12N2740/16063 , C12N2740/16122 , C12N2740/16222 , Y02A50/466
摘要： A method of making an immunogenic composition using inactivated HIV Inactivation of HIV is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H.A method of making an immunogenic composition using inactivated HIV. Inactivation of HIV is through psoraten and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H.
摘要翻译：使用灭活的HIV制备免疫原性组合物的方法HIV的失活通过补骨脂素和紫外线辐射。通过去除干扰免疫应答的HIV的结构特征，使组合变得更有效。特别地，除去唾液酸以增强组合物的免疫识别并损害补体因子H结合。还除去CD55和CD59以防止补体因子H的结合。使用灭活的HIV制备免疫原性组合物的方法。艾滋病毒的灭活是通过吸收和紫外线辐射。通过去除干扰免疫应答的HIV的结构特征，使组合变得更有效。特别地，除去唾液酸以增强组合物的免疫识别并损害补体因子H结合。 CD55和CD59也被去除以防止补体因子H的结合。

138. 发明申请

US20090098144A1 IMMUNOGEN PRESENTING HIV GP120 V3 LOOP IN A CONFORMATION THAT INDUCES BROADLY NEUTRALIZING ANTIBODIES 有权
标题翻译：免疫细胞提供HIV GP120 V3环路，诱导大量中和抗体
公开(公告)号：US20090098144A1
公开(公告)日：2009-04-16
申请号：US12195318
申请日：2008-08-20
申请人： Susan ZOLLA-PAZNER , Miroslaw K. Gorny , Timothy J. Cardozo , Xiang-peng Kong , Ruben Abagyan , Maxim Totrov , Shan Lu , Abraham Pinter
发明人： Susan ZOLLA-PAZNER , Miroslaw K. Gorny , Timothy J. Cardozo , Xiang-peng Kong , Ruben Abagyan , Maxim Totrov , Shan Lu , Abraham Pinter
IPC分类号： A61K39/42 , C07K16/10 , A61P31/18
CPC分类号： C07K14/005 , A61K38/03 , A61K38/16 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/53 , A61K2039/545 , A61K2039/55555 , C07K2319/35 , C07K2319/55 , C12N2740/16122 , C12N2740/16134 , Y02A50/472
摘要： Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related E. coli enterotoxins. Such immunogenic polypeptides induce broadly reactive anti-gp120 antibodies specific for V3 epitopes that can neutralize heterologous HIV-1 subtypes and strains. These polypeptide, methods for preparing them, and methods for inducing anti-gp120 (V3-specific) antibody) responses using them are disclosed.
摘要翻译：将HIV-1 V3环肽从病毒糖蛋白gp120插入到选定的免疫原性支架蛋白中导致重组多肽，其是有效的V3免疫原。 V3免疫原包括天然和共有的V3序列和环状和反向肽。优选的支架蛋白是霍乱毒素亚基B及其同系物，包括密切相关的大肠杆菌肠毒素。这样的免疫原性多肽诱导可以中和异源HIV-1亚型和菌株的V3表位特异性的广泛反应性抗gp120抗体。公开了这些多肽，其制备方法和诱导抗gp120（V3特异性）抗体的方法）。

139. 发明申请

US20090093402A1 Albumin Fusion Proteins 审中-公开
公开(公告)号：US20090093402A1
公开(公告)日：2009-04-09
申请号：US11929702
申请日：2007-10-30
申请人： Craig A. Rosen , William A. Haseltine , David J. Ballance , Andrew J. Turner , Steven M. Ruben
发明人： Craig A. Rosen , William A. Haseltine , David J. Ballance , Andrew J. Turner , Steven M. Ruben
IPC分类号： A61K38/00 , C07K14/00 , C07H21/00 , A61P43/00
CPC分类号： C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

140. 发明申请

US20090081124A1 VIRUS COAT PROTEIN/RECEPTOR CHIMERAS AND METHODS OF USE 有权
标题翻译：病毒蛋白蛋白/受体CHIMERAS及其使用方法
公开(公告)号：US20090081124A1
公开(公告)日：2009-03-26
申请号：US11940445
申请日：2007-11-15
申请人： Anthony Louis DeVico , Timothy R. Fouts , Robert G. Tuskan
发明人： Anthony Louis DeVico , Timothy R. Fouts , Robert G. Tuskan
IPC分类号： A61K49/00 , C07K14/00 , C07K16/00 , C07H21/00 , C12N15/63 , A61P31/18 , C12N5/00 , A61K31/44 , C12Q1/70
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07K14/70514 , C07K16/1063 , C07K16/2812 , C07K2317/34 , C07K2319/00 , C07K2319/30 , C07K2319/32 , C07K2319/40 , C07K2319/41 , C07K2319/735 , C12N15/62 , C12N2740/16122 , G01N33/56983 , G01N33/56988 , G01N2500/00
摘要： The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occn-panty of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences.
摘要翻译：本发明涉及包含能够相互作用以形成能够结合共受体的复合物的病毒外壳序列和受体序列的嵌合分子。因此，这样的嵌合分子显示出受体外壳蛋白复合物特征的功能特性，并且可用作例如抑制细胞上存在的共 - 受体的隐窝的细胞的病毒感染的试剂。在具体方面，嵌合多肽包括免疫缺陷病毒包膜多肽，例如HIV，SIV，FIV，FeLV，FPV和疱疹病毒的多肽。适用于嵌合多肽的受体序列包括例如CCR5和CXCR4序列。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式